

Short Name	Comments	Type	Investigator	Contact
Epilepsy				
Nautilus	RNS® System Responsive Thalamic Stimulation for Primary Generalized Seizures Study	Device	Dr. David Burdette	Katie Dykstra katie.dykstra@spectrumhealth.org 616.486.0936
<p><i>The purpose of this trials is to demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures for those 12 years of age or older who have drug-resistant idiopathic generalized epilepsy</i></p>				
PACIFIC	A Phase 1b/2a randomized, double-blind, placebo-controlled, parallel-group dose escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies	Treatment	Dr. David Burdette	Heather Brooks heather.benningfield@spectrumhealth.org 616.391.9365 Katie Dykstra katie.dykstra@spectrumhealth.org 616.486.0936
<p><i>The purpose of this trial is to evaluate the safety and effectiveness of LP352 for the treatment of adolescent and adults with developmental and epileptic encephalopathies</i></p>				